companydirectorylist.com  Global Business Directories and Company Directories
Search Business,Company,Industry :


Country Lists
USA Company Directories
Canada Business Lists
Australia Business Directories
France Company Lists
Italy Company Lists
Spain Company Directories
Switzerland Business Lists
Austria Company Directories
Belgium Business Directories
Hong Kong Company Lists
China Business Lists
Taiwan Company Lists
United Arab Emirates Company Directories


Industry Catalogs
USA Industry Directories














  • Tempus | AI-enabled precision medicine
    Tempus has built the world’s largest library of clinical molecular data and an operating system to make that data accessible and useful, starting with cancer
  • Tempus AI - Wikipedia
    Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM " [6][7]
  • Tempus AIs Strategic Push to Expand Beyond Oncology
    Tempus AI TEM is developing and deploying a suite of advanced algorithms and diagnostic software that run on its multimodal data These algorithms span beyond oncology, including digital pathology
  • Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
    Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner
  • Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
    Tempus AI is a healthcare technology company focused on advancing precision medicine through artificial intelligence The company aggregates and structures multimodal clinical and lab data, then provides AI-enabled solutions to physicians, researchers, payers, and biopharma companies
  • Is Tempus AI the Next Big Artificial Intelligence Stock to Buy?
    Tempus AI has over 400 petabytes of healthcare data, which can be highly valuable when training AI models
  • Tempus | SoftBank Group Corp.
    Launched in the United States in 2015, Tempus is now one of the largest sequencers of cancer patients in the world Having built its platform for oncology, it has expanded to neuropsychiatry, cardiology, infectious disease, and radiology
  • Is Tempus AI Still Attractive After Its 121. 5% Surge and AI Healthcare . . .
    If you have been wondering whether Tempus AI's rapid rise is justified or if the stock is already priced for perfection, you are not alone After a strong run, the stock is still up 121 5% year to date, including a 6 0% gain over the last month and 2 6% over the past week This suggests that sentiment is anything but neutral Much of this excitement has been driven by Tempus AI's expanding




Business Directories,Company Directories
Business Directories,Company Directories copyright ©2005-2012 
disclaimer